Young Plasma Transfusion for Health & Longevity - Quick Reference Sheet

Young Plasma Transfusion for Health & Longevity

Created on 10/09/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Young plasma transfusion is an intravenous infusion of plasma, the liquid part of blood, from donors in their late teens to twenties, given to older recipients, hoping to shift aspects of aging. Human studies are few, small and short, and no benefit reaches the higher evidence levels. Allergic reactions have appeared in trials of more than one group. Regulators state the product is not approved for aging. (Full Review)

Protocol

Stanford infusion protocol (Wyss-Coray group)
1 unit (about 250 mL) once weekly for 4 weeks
Young fresh frozen plasma from male donors aged 18 to 30, then a 6-week washout
Plasma-fraction protocol (Alkahest)
100 mL or 250 mL daily for 5 consecutive days
Plasma protein fraction GRF6019, repeated after a 3-month interval
Young-donor plasma exchange (Oslo group)
16 to 26 L of patient plasma replaced
Donors aged 18 to 24; three protocol variants differing in intensity and dose; calcium before sessions
Time to effect
Stanford trial
After 4 weekly infusions
When outcomes were assessed; time to effect not established
Plasma-fraction trial
At 24 weeks
When outcomes were assessed; time to effect not established
Healthy adults
Not established
No trial has shown when benefit appears in healthy adults

Benefits

Contraindications
  • Prior severe allergic reaction to plasma, or IgA deficiency with anti-IgA antibodies (theoretical)
  • Heart disease prone to fluid overload, outside supervised trials (trials excluded heart failure of New York Heart Association class II or higher, or class III–IV)
  • Active infection
  • Anemia under evaluation (treatment postponed until the workup is complete)
Key Interactions
  • Warfarin: caution (theoretical)
  • Direct oral anticoagulants (apixaban, rivaroxaban) and heparin (enoxaparin): monitor (theoretical)
  • Blood-pressure drugs (angiotensin-converting enzyme inhibitors such as lisinopril, angiotensin receptor blockers such as losartan): caution (theoretical)
  • Aspirin and NSAIDs (ibuprofen, naproxen): monitor (theoretical)
  • Antihistamines (cetirizine, diphenhydramine): monitor (theoretical)
  • Calcium supplements: beneficial interaction
  • Supplements with antiplatelet effects (fish oil, vitamin E, ginkgo, garlic): monitor (theoretical)
  • Intravenous immunoglobulin added to plasma exchange: caution

Risk & Side Effects

  • High: Allergic reactions, including urticaria and anaphylaxis
  • Medium:
  • Low: Transfusion-associated circulatory overload; transfusion-related acute lung injury; febrile and hypotensive reactions; plasma-exchange procedure effects, including low blood calcium; bleeding or hematoma at the venous access site; mild infusion-related symptoms; infectious disease transmission; possible tumor promotion; serious infection after intensive plasma exchange
  • Speculative: Epigenetic age acceleration after plasma removal

Monitoring

Marker Target Why
Total calcium 8.6–10.3 mg/dL (standard reference range) Safety check: exchange can lower calcium
Hemoglobin and platelet count Hemoglobin 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; platelets 150–450 ×10⁹/L (standard reference range) Safety check: baseline anemia delayed Oslo treatments
Fibrinogen and INR Fibrinogen 200–400 mg/dL; INR 0.8–1.1 (standard reference range) Safety check: exchange removes clotting factors; warfarin users need INR tracking
Albumin and total protein Albumin 3.5–5.0 g/dL; total protein 6.0–8.3 g/dL (standard reference range) Marker expected to change: plasma removal lowered both
Immunoglobulins (IgG, IgA, IgM) IgG 700–1,600 mg/dL; IgA 70–400 mg/dL; IgM 40–230 mg/dL (standard reference range) Safety check: low IgA flags allergic risk; levels may fall with exchange
Epigenetic age (DNA methylation clocks) No established target; track change from the individual's own baseline Marker expected to change in trials, though an unvalidated surrogate

Cadence: Baseline testing before any session; vital signs at every session; biochemistry about every 3 to 6 sessions in the Oslo pilot, then at 4 weeks and every 3 to 6 months after a course (common practice)

Qualitative Assessment

  • Sleep quality
  • Energy levels
  • Cognitive clarity
  • Caregiver-rated everyday function